Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 莫树锦教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1517/14740338.2011.540799 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/10WOS source URL
其它资讯
摘要Importance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for advanced pancreatic cancer. The oral administration and manageable toxicity of erlotinib, along with its similar efficacy to chemotherapy, make it an important option as either maintenance therapy or in second-/third-line for patients with NSCLC who have previously received first-line chemotherapy. It is also an emerging option in other treatment settings in NSCLC.
着者Reck M, Mok T, Wolf J, Heigener D, Wu YL
期刊名称Expert Opinion on Drug Safety
出版年份2011
月份1
日期1
卷号http://aims.cuhk.edu.hk/converis/portal/Publication/10
期次1
出版社Taylor & Francis: STM, Behavioural Science and Public Health Titles
页次147 - 157
国际标準期刊号1474-0338
电子国际标準期刊号1744-764X
语言英式英语
关键词EGFR; erlotinib; NSCLC; TKI
Web of Science 学科类别Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY
